Visual impairment can be a major health issue for older adults, ranging from a minor inconvenience to vision loss significantly impacting quality of life. Age-related macular degeneration (AMD) is a neurodegenerative disease of the retina and would fall into the latter category. It’s the leading cause of irreversible vision loss among the elderly. In 2016, […]
New Developments in Macular Degeneration/Diabetic Eye Disease Read More »
While much of the world was on pause during the COVID-19 pandemic, there are definite signs that even a pandemic cannot hold back drug innovation. Despite the variety of challenges posed by the dreaded contagion, the FDA continued to churn out drug approvals in 2021 and innovate health advancements for the American public. Historically, December
Drug Innovation Continues Despite a World-Wide Pandemic Read More »
See article as it originally appeared in MedCity News. The pharmaceutical industry made more headlines in 2021 than in any other year in recent memory. And 2022 is set to be a monumental year as well. Here are three key themes that will define the year ahead. Biosimilar interchangeability In 2021 the FDA approved the
Three Pharmacy Trends That Will Define 2022 Read More »
Download our 2022 Q1 Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest
2022 Q1 RemedyOne Quarterly Pipeline Report Read More »
Healthcare payers may not be familiar with the high costs of paroxysmal nocturnal hemoglobinuria (PNH), or even know what it is, that is until the ultra-expensive drugs prescribed to treat this condition start showing up on claim reports. With a yearly cost of treatment reaching nearly $1MM, payers and patients alike need to be considered
High Cost, Lifelong Treatments and the Impact on Payers and Patients Read More »
It might seem like a lowest-net-cost formulary would be made up of clinically equivalent agents with the lowest overall cost. But in the complex world of drug pricing and pharmacy benefits, that is not the case. Lowest-net-cost formularies are a good way for organizations to lower their pharmacy spend. These formularies substitute clinically sound, chemically
Want the Lowest-Net-Cost Drugs? Change Your Thinking on Disruption Read More »
Introduction Recent data from Johns Hopkins University showed over 760,000 people in the U.S. have died from the coronavirus to date. According to a September 2021 report from the CDC, unvaccinated people are 10 times more likely to get hospitalized and die from COVID-19 than fully vaccinated people. COVID-19 vaccines can protect against infection but
COVID-19 Treatment Developments Read More »
The Latest Developments in Drug Approvals Each quarter, the RemedyOne Clinical team curates a drug pipeline report for our clients that shares insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful
Q3 2021 Drug Pipeline Recap Read More »
Download our 2021 Q4 Quarterly Drug Pipeline Report Our quarterly pipeline report provides insight into specialty and traditional drugs in development that are expected to launch within the next twelve months, with a focus on medications currently in Phase III studies. The report is a helpful tool for your team to keep updated on the latest
2021 Q4 RemedyOne Quarterly Pipeline Report Read More »
Gene therapies are here and they have the potential to be miraculous. And extremely expensive. The science behind these therapies are truly the realization of a sci-fi promise — that science can alter genes in a cell to eliminate a disease. The price tags — upwards of $2 million per patient — feel like something out
No One Really Knows How We’ll Pay for Gene Therapies Read More »
